M&A Deal Summary

GlycoMimetics Acquires Crescent Biopharma

On October 29, 2024, GlycoMimetics acquired life science company Crescent Biopharma

Acquisition Highlights
  • This is GlycoMimetics’ 1st transaction in the Life Science sector.
  • This is GlycoMimetics’ 1st transaction in the United States.

M&A Deal Summary
Date 2024-10-29
Target Crescent Biopharma
Sector Life Science
Buyer(s) GlycoMimetics
Deal Type Add-on Acquisition
Advisor(s) Wedbush Securities, Inc.
Jefferies
Stifel, Nicolaus & Co., Inc.
LifeSci Capital (Financial)
Gibson, Dunn & Crutcher (Legal)

Target

Crescent Biopharma

United States
Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. Crescent Biopharma is based in United States.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

GlycoMimetics

Rockville, Maryland, United States
Category Company
Founded 2003
Sector Life Science
DESCRIPTION

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. GlycoMimetics was founded in 2003 and is based in Rockville, Maryland.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal